

CureColla® 21 and a portfolio of Type XXI collagen-derived peptide actives from the COL21-ECM™ Library

BeautyX Group Co., Ltd.

col21-ecm-library.biolijunxiang.chatgpt.site

PRODUCT/SERVICE BACKGROUND INFORMATION

The company specializes in recombinant collagen and extracellular matrix (ECM) bioactives. Supported by a multidisciplinary R&D team and long-term research collaboration with the Yangtze Delta Region Institute of Tsinghua University and China Pharmaceutical University, the company integrates protein engineering, biomanufacturing and biological evaluation. Its proprietary Type XXI collagen platform underpins CureColla® 21 and the COL21-ECM™ Library, which combines microbiome-inspired enzymatic hydrolysis and AI screening to discover functional collagen-derived signaling peptides for personal care.

WHAT IS THE COMPANY INTRODUCING TO THE MARKET/INDUSTRY?

The company introduces CureColla® 21 and a portfolio of Type XXI collagen-derived peptide actives from the COL21-ECM™ Library. CureColla® Stem 21 combines a collagen peptide with spirulina-derived PDRN for skin rejuvenation; CureColla® Shine 9AA targets brightening; CureColla® Hair 21 supports scalp and follicle care; and CureColla® Oral 21 supports oral comfort and gingival soft-tissue health. The portfolio translates a common collagen discovery platform into differentiated ingredients for skincare, scalp care and oral care formulations.

HOW WILL THIS NEW PRODUCT/SERVICE IMPACT THE INDUSTRY (BENEFITS)?

The platform expands collagen innovation toward defined signaling peptides and function-specific personal care applications. By connecting microbiome-inspired peptide discovery with AI screening and biological evaluation, it offers formulators a systematic route to ECM-derived actives. The portfolio supports development of products addressing visible aging, uneven skin tone, scalp health and oral comfort, with cell-based and ex vivo studies informing ingredient selection.